Diarmuid Coughlan

Search results

• 2024

  Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909)

  Llewellyn, A., Coughlan, D., Umemneku-Chikere, C., Fulbright, H., Nevitt, S. J. & Hodgson, R., 15 Nov 2024, National Institute for Health and Care Excellence.

  Research output: Book/Report › Commissioned report

• Quizartinib for untreated FLT3-ITD-positive acute myeloid leukaemia: A Single Technology Appraisal

  Nevitt, S. J., Llewellyn, A., Deng, J., Coughlan, D., Anwer, S., Marshall, D., Harden, M. & Hodgson, R., 12 Jun 2024, National Institute for Health and Care Excellence.

  Research output: Book/Report › Commissioned report